XML 43 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Business Segments and Geographic Information
 12 Months Ended
Sep. 27, 2025
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic Information
The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the products are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable products and supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company’s chief executive officer is the chief operating decision maker (“CODM”). The Company measures and evaluates its reportable segments based on segment revenues and segment operating income (loss), which includes cost of revenues and operating expenses. The Company allocates the cost of corporate functions, including depreciation expense, to its segments at predetermined rates. The Company excludes from segment expenses and segment operating income certain transactions and expenses that the CODM considers to not be representative of core operating performance, such as amounts related to intangible asset amortization expense, goodwill and intangible asset impairment charges, transaction and integration expenses for acquisitions and other acquisition related charges, restructuring, consolidation and divestiture charges, legal settlements, and other one-time or unusual items.
The CODM uses segment revenues and segment operating income (loss) primarily in the budget, forecasting and quarterly business review processes. During these evaluations, the CODM analyzes budget and forecast versus actual results, which are used to assess the performance of reportable segments and to allocate resources across reportable segments. The table below reconciles segment revenues to segment operating income (loss) with the expense categories presented reflecting the expenses that the Company has determined to be significant segment expenses. Significant segment expenses are the expense categories that are regularly provided to the CODM for decision making.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company has presented all other identifiable assets as corporate assets.
Year Ended September 27, 2025
Diagnostics
Breast Health
GYN Surgical
Skeletal Health
Consolidated
Total revenues
$1,827.2 $1,484.1 $679.8 $109.4 $4,100.5 
Segment expenses:
Cost of revenues
689.6 611.2 208.3 90.3 1,599.4 
Research and development126.7 84.5 31.9 2.7 245.8 
Sales and marketing
228.8 198.5 167.1 9.4 603.8 
General and administrative
182.2 153.1 67.9 10.7 413.9 
Segment income (loss) from operations
$599.9 $436.8 $204.6 $(3.7)$1,237.6 
Unallocated amounts:
Cost of revenue adjustments(1)
23.3 
Amortization of acquired intangible assets190.9 
Impairment of intangible assets and equipment
225.9 
Restructuring, integration and acquisition-related charges
76.0 
Other operating expense adjustments
7.2 
Income from operations
$714.3 
Interest expense, net
(42.7)
Foreign currency and other non-operating income, net
9.6 
Income before income taxes
$681.2 
(1) Primarily related to the fair value write-up of inventory sold related to the Gynesonics acquisition and costs associated with the shutdown of the Manchester, England manufacturing location, primarily accelerated depreciation and excess inventory charges.
Year Ended September 27, 2025
DiagnosticsBreast HealthGYN SurgicalSkeletal Health
Corporate
Consolidated
Depreciation and amortization
$199.4 $51.3 $48.2 $0.9 $— $299.8 
Capital expenditures
86.7 19.9 25.1 0.4 4.9 137.0 
Identifiable assets
2,244.0 1,531.3 1,644.9 31.2 3,563.5 9,014.9 
Year Ended September 28, 2024
Diagnostics
Breast Health
GYN Surgical
Skeletal Health
Consolidated
Total revenues
$1,782.0 $1,522.9 $641.3 $84.1 $4,030.3 
Segment expenses:
Cost of revenues
700.2 631.1 179.5 60.6 1,571.4 
Research and development151.0 79.4 28.9 3.4 262.7 
Sales and marketing
239.1 191.7 144.7 9.8 585.3 
General and administrative
182.2 144.0 63.7 10.8 400.7 
Segment income (loss) from operations
$509.5 $476.7 $224.5 $(0.5)$1,210.2 
Unallocated amounts:
Cost of revenue adjustments(2)
11.4 
Amortization of acquired intangible assets209.7 
Impairment of intangible assets and equipment
44.8 
Restructuring, integration and acquisition-related charges
51.7 
Other operating expense adjustments
10.0 
Income from operations
$882.6 
Interest expense, net
(13.4)
Foreign currency and other non-operating expenses, net
(4.1)
Income before income taxes
$865.1 
(2) Primarily related to the fair value write-up of inventory sold related to the Endomagnetics acquisition and charges for non-cancelable purchase orders related to a product line discontinuance in the Diagnostics division.
Year Ended September 28, 2024
DiagnosticsBreast HealthGYN SurgicalSkeletal Health
Corporate
Consolidated
Depreciation and amortization
$218.8 $41.6 $48.1 $0.5 $— $309.0 
Capital expenditures
80.2 30.9 16.6 1.4 1.1 130.2 
Identifiable assets
2,431.3 1,588.9 1,419.9 48.3 3,667.6 9,156.0 
Year Ended September 30, 2023
Diagnostics
Breast Health
GYN Surgical
Skeletal Health
Consolidated
Total revenues
$1,880.1 $1,432.7 $604.2 $113.4 $4,030.4 
Segment expenses:
Cost of revenues
699.1 609.0 164.2 76.8 1,549.1 
Research and development157.1 95.0 35.5 5.0 292.6 
Sales and marketing
248.6 193.0 144.6 9.1 595.3 
General and administrative
177.5 142.2 56.8 9.7 386.2 
Segment income from operations
$597.8 $393.5 $203.1 $12.8 $1,207.2 
Unallocated amounts:
Cost of revenue adjustments(3)
24.6 
Amortization of acquired intangible assets233.8 
Impairment of intangible assets and equipment
223.8 
Loss on assets held-for-sale
51.7 
Restructuring, integration and acquisition-related charges
14.1 
Contingent consideration adjustments(14.9)
Other operating expense adjustments5.7 
Income from operations
$668.4 
Interest income, net
9.4 
Foreign currency and other non-operating expense, net
(1.7)
Income before income taxes
$676.1 
(3) Primarily related to the write off of inventory related to a product line discontinuance in the Diagnostics division.
Year Ended September 30, 2023
DiagnosticsBreast HealthGYN SurgicalSkeletal Health
Corporate
Consolidated
Depreciation and amortization
$224.7 $50.0 $48.0 $0.7 $— $323.4 
Capital expenditures
85.2 41.1 17.0 0.8 6.1 150.2 
Segment assets
2,596.4 1,170.1 1,455.4 33.7 3,883.7 9,139.3 
The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy, and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of world” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 Years Ended
 September 27,
2025		September 28,
2024		September 30,
2023
United States74.3 %75.0 %75.9 %
Europe14.5 %13.2 %12.9 %
Asia-Pacific5.9 %6.5 %6.3 %
Rest of world5.3 %5.3 %4.9 %
100.0 %100.0 %100.0 %
The Company’s property, plant and equipment were geographically located as follows:
September 27, 2025September 28, 2024September 30, 2023
United States$412.5 $379.7 $367.6 
Europe74.1 70.6 67.0 
Costa Rica38.0 40.0 36.0 
United Kingdom16.6 32.0 32.4 
Rest of world18.4 15.5 14.0 
$559.6 $537.8 $517.0